Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) will post its quarterly earnings results after the market closes on Thursday, March 30th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.70) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.
Eledon Pharmaceuticals Stock Performance
Shares of NASDAQ ELDN opened at $2.35 on Wednesday. The company has a market capitalization of $32.27 million, a P/E ratio of -0.88 and a beta of 2.04. Eledon Pharmaceuticals has a 52-week low of $1.90 and a 52-week high of $4.15. The company’s 50 day moving average price is $2.69 and its 200-day moving average price is $2.64.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating on shares of Eledon Pharmaceuticals in a research report on Thursday, December 15th.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp lifted its stake in Eledon Pharmaceuticals by 10.5% in the first quarter. State Street Corp now owns 44,692 shares of the company’s stock worth $176,000 after acquiring an additional 4,257 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Eledon Pharmaceuticals by 35.1% during the 1st quarter. Renaissance Technologies LLC now owns 18,473 shares of the company’s stock valued at $73,000 after buying an additional 4,800 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Eledon Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 679,243 shares of the company’s stock valued at $2,676,000 after buying an additional 9,543 shares in the last quarter. Ensign Peak Advisors Inc boosted its holdings in shares of Eledon Pharmaceuticals by 13.2% during the 3rd quarter. Ensign Peak Advisors Inc now owns 87,286 shares of the company’s stock valued at $241,000 after buying an additional 10,186 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Eledon Pharmaceuticals in the 3rd quarter worth about $50,000. 45.59% of the stock is currently owned by institutional investors.
Eledon Pharmaceuticals Company Profile
Eledon Pharmaceuticals, Inc is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential.
Read More
Receive News & Ratings for Eledon Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.